Eplerenone Versus Spironolactone as Treatment of Ascites Due to Liver Cirrhosis; a Study of Efficacy and Side Effects
Status:
Withdrawn
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This study compares Spironolactone, a non-selective aldosterone antagonist, with Eplerenone,
a selective aldosterone antagonist, regarding efficacy and hormonal side effects when
treating male cirrhotic patients with uncomplicated ascites over a 6 month period. The
investigators hypothesis is that Eplerenone is as effective as Spironolactone as treatment of
ascites with less side effects such as painful gynecomastia.
Phase:
Phase 2
Details
Lead Sponsor:
Emma Nilsson
Collaborators:
Göteborg University Karolinska University Hospital Region Örebro County University Hospital, Linkoeping University Hospital, Umeå Uppsala University Hospital